generic drug simply generic pharmaceutical drug contains chemical substance drug originally protected chemical patents generic drugs allowed sale patents original drugs expire active chemical substance medical profile generics equivalent performance compared performance time patented generic drug active pharmaceutical ingredient api original may differ characteristics manufacturing process formulation excipients color taste although may associated particular company generic drugs usually subject government regulations countries dispensed labeled name manufacturer generic nonproprietary name united states adopted name usan international nonproprietary name inn drug generic drug must contain active ingredients original brandname formulation us food drug administration fda requires generics identical within acceptable bioequivalent range brandname counterparts respect pharmacokinetic pharmacodynamic fdas use word identical legal interpretation literalcitation needed biopharmaceuticals monoclonal antibodies differ biologically smallmolecule drugs biosimilars active pharmaceutical ingredients almost identical original product typically regulated extended set rules generic drugs active ingredients reference cases generic products become available patent protections afforded drugs original developer expire generic drugs enter market competition often leads substantially lower prices original brandname product generic equivalents countries patents give years protection however many countries regions european union united may grant five years additional protection patent term restoration manufacturers meet specific goals conducting clinical trials pediatric manufacturers wholesalers insurers drugstores increase prices various stages production according analysis generic pharmaceutical association generic drugs accounted percent billion prescriptions filled united branded generics hand defined fda national health service products either novel dosage forms offpatent products produced manufacturer originator molecule b molecule copy offpatent product trade since company making branded generics spend little research development able spend marketing alone thus earning higher profits driving costs example largest revenues ranbaxy owned sun pharma came branded generic drug names constructed using standardized affixes distinguish drugs within classes suggest actioncitation needed pharmaceutical company first markets drug usually patent expires company use exclude competitors suing patent pharmaceutical companies develop new drugs generally invest drug candidates strong patent protection strategy recoup costs drug development including costs drug candidates fail make average cost brandname company discovering testing obtaining regulatory approval new drug new chemical entity estimated much million billion drug companies bring new products several product line extension strategies use extend exclusivity seen gaming system labeled evergreening critics point patent protection long drug patent lasts brandname company enjoys period market exclusivity monopoly company able set price drug level maximizes profit profit often greatly exceeds development production costs drug allowing company offset cost research development drugs profitable pass clinical impact loss patent exclusivity pharmaceutical products varies significantly across different product classes eg biologics vs small molecules largely due regulatory legal manufacturing hurdles associated products indeed greater degree brandbrand competitive dynamics seen biologics complex generics space allows manufacturers originators better protect market share following loss patent large pharmaceutical companies often spend millions protecting patents generic apart litigation may reformulate drug license subsidiary another company sell generics original patent generics sold license patent holder known authorized generic drugs usually sold significantly lower prices branded equivalents lower profit one reason competition increases among producers drug longer protected generic companies incur fewer costs creating generic cost manufacturing without costs drug discovery drug therefore able maintain profitability lower prices often low enough users lessprosperous countries afford example thailand imported millions doses generic version bloodthinning drug plavix used help prevent heart attacks india leading manufacturer generic drugs cost per generic drug companies may also receive benefit previous marketing efforts brandname company including advertising presentations drug representatives distribution free samples many drugs introduced generic manufacturers already market decade may already well known patients providers although often branded namecitation needed india leading country worlds generic drugs market exporting billion worth drugs india exports generic drugs united states european also according market research community global generic drugs market evaluated million expected rise cagr forecast united kingdom generic drug pricing controlled governments reimbursement rate price paid pharmacists doctors determined mainly number license holders sales value original brand ease manufacture typical price decay graph show scalloped usually starts brandname price day generic launch falls competition intensifies years graph typically flattens approximately original brand price cases price bounces license holders withdraw market selling price dips cost goods price rises license holders reenter market new nhs spent billion generic medicines percent prescriptions us filled generic use generic drugs united states led billion health care generics industry began transitioning end era giant patent cliffs pharmaceutical industry patented drugs sales around billion set come patent billion revenue set open competition less next year companies industry responded consolidation turning try generate new developed nations require generic drug manufacturers prove formulations bioequivalent brandname bioequivalence mean generic drugs must exactly brandname product pharmaceutical equivalent chemical differences may exist different salt ester may used instance different inactive ingredients means generic may look different originator however therapeutic effect drug must pharmaceutical alternativecitation needed small molecule drugs accepted bioequivalent pharmacokinetic parameters area curve auc maximum concentration cmax within confidence interval approved generics us well within complex inhalers patch delivery systems liposomal preparations biosimilar pharmacodynamic clinical equivalence enacted drug price competition patent term restoration act informally known act standardized procedures recognition generic drugs fda launched generic initiative value efficiency effort modernize streamline generic drug approval process increase number variety generic products availablecitation needed company market generic drug needs file abbreviated new drug application anda food drug administration seeking demonstrate therapeutic equivalence previously approved referencelisted drug proving manufacture drug safely anda approved fda requires confidence interval geometric mean testreference ratios total drug exposure represented area curve auc maximum plasma concentration cmax fall within limits range part statistical calculation mean generic drugs allowed differ brandname counterparts percent fda evaluated studies conducted compared absorption brandname generic drugs persons body average difference absorption generic brandname drug percent comparable difference two batches brandname noninnovator versions biologic drugs biosimilars require clinical trials immunogenicity addition tests establishing bioequivalency products entirely identical batchtobatch variability biological nature subject extra application approved fda adds generic drug approved drug products therapeutic equivalence evaluations list annotates list show equivalence referencelisted drug generic fda also recognizes drugs use ingredients different bioavailability divides therapeutic equivalence example diltiazem hydrochloride four equivalence groups using active ingredient considered equivalent within order start selling drug promptly patent innovator drug expires generic company file anda well patent expires puts generic company risk sued patent infringement since act filing anda considered constructive infringement order incentivize generic companies take risk hatchwaxman act granted administrative exclusivity period generic drug manufacturers first file faced patent litigation drug innovator patent holder generic companies often countersue challenging validity like litigation private parties innovator generic companies may choose settle litigation settlement agreements struck courts took form reverse payment patent settlement agreements generic company basically accepts payment drop litigation delaying introduction generic product frustrating purpose innovator companies sometimes try maintain revenue drug patents expire allowing another company sell authorized generic ftc report found consumers benefitted lower costs authorized generic introduced day exclusivity period created innovator companies may also present arguments fda anda accepted filing fda citizen petition right individuals organizations petition federal government guaranteed first amendment united states reason fda promulgated regulations provide among things time interested person request fda issue amend revoke regulation order set forth procedure generic drugs viewed suspicion doctors example warfarin coumadin narrow therapeutic window requires frequent blood tests make sure patients subtherapeutic toxic level study performed ontario showed replacing coumadin generic warfarin many physicians comfortable patients taking branded generic countries example australia drug prescribed one brand name doctors may choose allow pharmacists substitute brand different one prescribed unless consumer requests series scandals around approval generic drugs late shook public confidence generic drugs several instances companies obtained bioequivalence data fraudulently using branded drug tests instead product congressional investigation found corruption fda employees accepting bribes approve generic companies applications delaying denying north carolina public radios peoples pharmacy began reporting consumers complaints generic versions bupropion wellbutrin yielding unexpected subsequently impax laboratoriess mg extendedrelease tablets marketed teva pharmaceutical industries withdrawn us market fda determined problems quality generic drugs especially produced outside united states widespread fda infrequent less annual inspections production sites outside united states fda normally gives advance notice inspections lead coverups problems inspectors arrive inspections performed little advance notice produced evidence serious problems majority generic drug manufacturing sites india two women claiming suffered severe medical complications generic version metoclopramide lost supreme court appeal june ruling pliva inc v court held generic companies held liable information lack information originators indian government began encouraging drug manufacturing indian companies early patents act patents act removed composition patents foods drugs though kept process patents shortened period five seven years resulting lack patent protection created niche indian global markets indian companies filled reverseengineering new processes manufacturing lowcost code ethics issued medical council india calls physicians prescribe drugs generic names india leading country worlds generic drugs market sun pharmaceuticals largest pharmaceutical company india indian generics companies exported billion worth drugs year bioequivalence studies required generics drugs less four years old since generic drugs certain classes irrespective age require bioequivalence generic drug production large part pharmaceutical industry china western observers said china lacks administrative protection however entry world trade organization brought stronger patent china remains largest exporter active pharmaceutical ingredients accounting world market per bioequivalence studies required new generic drugs starting older drugs planned well addition vitro dissolution behavior required since classes drugs exempt testing requiring dissolution check classes require simplified several major companies traditionally dominate generic drugs market including viatris merger mylan upjohn teva novartis sandoz sun prices traditional generic drugs declined newer companies indiabased sun pharma aurobindo pharma dr reddys laboratories well canadabased apotex taken market share led focus biosimilars httpsenwikipediaorgwikiaffordabledrugs